support@nanobiousa.com

1-888-678-8889 (USA)

3WJ – targeting ligand-antiMIR19
3WJ – targeting ligand-antiMIR19

Purpose:This nanoparticle can be used for specific delivery of anti-microRNA19 to cells in vitro and in vivo.

Get Quote
  Product Name Catalog number Synthesis scale
 
Triple Negative Breast Cancer (TNBC)
 
 
 
3WJ – RFA (TNBC)-antiMIR19 RNP-M19-01-1
1 nmol
RNP-M19-01-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and antiMIR19]

3WJ – RFM-antiMIR19   RNP-M19-07-1 1 nmol
RNP-M19-07-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR19]

3WJ – RFA(TNBC)-Scr    RNP-MSc-01-1
1 nmol
RNP-MSc-01-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Triple Negative Breast Cancer (TNBC) cells and scramble miRNA]

 
HER2+ 
Cancer
 
 
 
3WJ – RFA (HER2)-antiMIR19 RNP-M19-03-1
1 nmol
RNP-M19-03-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting HER2 + cancer cells and antiMIR19]

3WJ – RFM-antiMIR19  RNP-M19-07-1 1 nmol
RNP-M19-07-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR19]

3WJ – RFA(HER2)-Scr   RNP-MSc-03-1
1 nmol
RNP-MSc-03-2  
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting HER2 + cancer cells and scramble miRNA]

 
Folate Receptor+ Cancer 
 
 
 
 
3WJ – RFC (FA)-antiMIR19 RNP-M19-05-1
1 nmol
RNP-M19-05-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a folate ligand for targeting folate receptor (+) cells and antiMIR19]

3WJ – RF-antiMIR19  RNP-M19-08-1 1 nmol
RNP-M19-08-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle without ligand (serving as vector control) but with antiMIR19]

3WJ – RFC(FA)-Scr  RNP-MSc-05-1
1 nmol
RNP-MSc-05-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a folate ligand for targeting folate receptor (+) cells and scramble miRNA]

 
Epithelial
Cancer 
 
 
 
 
 
3WJ – RFA (EC)-antiMIR19 RNP-M19-04-1
1 nmol
RNP-M19-04-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Epithelial Cancer (EC) and anti-microRNA19]

3WJ – RFM-antiMIR19  RNP-M19-07-1 1 nmol
RNP-M19-07-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR19]

3WJ – RFA(EC)-Scr   RNP-MSc-04-1
1 nmol
RNP-MSc-04-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Epithelial Cancer (EC) cells and scramble miRNA]

 
Galactose Receptor+
Cancer 
 
 
 
 
3WJ – RFC (GL)-antiMIR19 RNP-M19-06-1
1 nmol
RNP-M19-06-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a galactose ligand for targeting liver cancer cells and antiMIR19]

3WJ – RF-antiMIR19    RNP-M17-08-1 1 nmol
RNP-M17-08-2  50 nmol

[Description: Serum stable 3WJ RNA nanoparticle without ligand (serving as vector control) but with antiMIR19]

3WJ – RFC(GL)-Scr  RNP-MSc-06-1
1 nmol
RNP-MSc-06-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a galactose ligand for targeting liver cancer cells and scramble miRNA]

 
PSMA+
Cancer 
 
 
 
 
3WJ – RFA (PC)-antiMIR19 RNP-M19-02-1
1 nmol
RNP-M19-02-2 
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and antiMIR19]

3WJ – RFM-antiMIR19    RNP-M19-07-1 1 nmol
RNP-M19-07-2 50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with a mutant aptamer (serving as a targeting control) and antiMIR19]

3WJ – RFA(PC)-Scr  RNP-MSc-02-1
1 nmol
RNP-MSc-02-2
50 nmol

[Description: Serum stable 3WJ RNA nanoparticle with an aptamer targeting Prostate Cancer (PC) cells and scramble miRNA]


Copyright © Nanobio Delivery Pharmaceutical Co., Ltd. All rights reserved.